Sanofi, Re­gen­eron bur­nish their block­buster Dupix­ent fran­chise with pos­i­tive re­sults in chil­dren with un­con­trolled eczema

As a sta­ble of new play­ers sets out to top­ple Dupix­ent’s sta­tus as the reign­ing an­ti­body treat­ment for atopic der­mati­tis, the block­buster’s de­vel­op­ers are mov­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER